Hematology

Latest News

FDA approved. | Image Credit: Pawel - stock.adobe.com
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

January 23rd 2025

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com
High Infection Risk in MM: Insights From the Pre-Immunotherapy Era

January 21st 2025

First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
Unmet Needs Remain in Secondary AML Following Treatment With HMAs

January 18th 2025

Man donating blood | Image Credit: © New Africa - stock.adobe.com
5 Medications That Defer Blood Donation

January 17th 2025

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

More News

Amgen Posts Updates on Triplet Therapy Using Carfilzomib
September 17th 2019

Amgen Posts Updates on Triplet Therapy Using Carfilzomib

AJMC Staff
Amgen recently announced early phase 3 CANDOR study data, showing the triple-drug combination of carfilzomib (Kyprolis), along with dexamethasone and daratumumab (Darzalex, sold by Janssen), met its primary end point of progression-free survival in patients with relapsed or refractory multiple myeloma, with a 37% reduction in the risk of progression or death.
Dr Ajai Chari Discusses the Importance of Real-World Evidence in Multiple Myeloma
September 11th 2019

Dr Ajai Chari Discusses the Importance of Real-World Evidence in Multiple Myeloma

Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
New Liquid Biopsy Test Found to Identify Patients Who May Respond to Immune Checkpoint Blockade
September 10th 2019

New Liquid Biopsy Test Found to Identify Patients Who May Respond to Immune Checkpoint Blockade

Matthew Gavidia
A new liquid biopsy test could detect microsatellite instability and tumor mutational burden, which can distinguish which patients are likely to respond to immune checkpoint inhibitors.
Dr John Fox Outlines Management Challenges in Multiple Myeloma
September 7th 2019

Dr John Fox Outlines Management Challenges in Multiple Myeloma

John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, discusses management challenges still facing providers treating multiple myeloma.
Study Explores Brentuximab Vedotin Efficacy in Patients Expressing High CD30 Levels
September 6th 2019

Study Explores Brentuximab Vedotin Efficacy in Patients Expressing High CD30 Levels

AJMC Staff
A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit.
New Treatment Can Benefit Patients With MM Refractory to Multiple Other Therapies
August 30th 2019

New Treatment Can Benefit Patients With MM Refractory to Multiple Other Therapies

Laura Joszt, MA
Patients with multiple myeloma (MM) who had disease progression on multiple therapies may benefit from treatment with the oral therapies selinexor and dexamethasone.
Dr John Fox Discusses Financial Toxicity Associated With Multidrug Regimens for Multiple Myeloma
August 29th 2019

Dr John Fox Discusses Financial Toxicity Associated With Multidrug Regimens for Multiple Myeloma

With an increase in the use of 3- and 4-drug regimens in multiple myeloma, providers are going to need to communicate the out-of-pocket costs when presenting treatment options so that patients can make an informed decision, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Dr Ajai Chari Outlines Disparities and Treatment Patterns in Multiple Myeloma
August 24th 2019

Dr Ajai Chari Outlines Disparities and Treatment Patterns in Multiple Myeloma

Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Study Finds Slow Uptake of New MM Therapies in Public Clinics in Latin America
August 13th 2019

Study Finds Slow Uptake of New MM Therapies in Public Clinics in Latin America

Laura Joszt, MA
In Latin America, there has been slower uptake of newer therapies to treat multiple myeloma (MM) in public clinics versus private clinics, which has led to disparities in outcomes.
Patients With Low-Risk Multiple Myeloma Precursor Can Progress to the Disease in Just 5 Years
August 10th 2019

Patients With Low-Risk Multiple Myeloma Precursor Can Progress to the Disease in Just 5 Years

Laura Joszt, MA
Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to researchers who are now recommending all patients with MGUS undergo blood testing and risk assessment.
Having a Close Relative With Blood Cancer Boosts One's Own Risk
August 8th 2019

Having a Close Relative With Blood Cancer Boosts One's Own Risk

Mary Caffrey
The study's lead author said more work is needed to develop screening protocols for people who may face familial risk of a blood cancer.
Dr Catherine Diefenbach Discusses Reducing Toxicity When Treating Lymphoma
August 2nd 2019

Dr Catherine Diefenbach Discusses Reducing Toxicity When Treating Lymphoma

Pairing low doses of chemotherapy with newer, targeted drugs can help prevent high toxicity, said Catherine Diefenbach, MD, director of clinical lymphoma at the NYU Langone Perlmutter Cancer Center.
Ibrutinib–Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia
August 1st 2019

Ibrutinib–Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia

Mary Caffrey
Patients with chronic lymphocytic leukemia (CLL) will likely see a new standard of care based on outcomes in a phase 3 trial for patients treated with a combination of ibrutinib and rituximab.
Mustang Bio Receives Orphan Drug Designation for Investigational CAR T-Cell Therapy for AML
July 27th 2019

Mustang Bio Receives Orphan Drug Designation for Investigational CAR T-Cell Therapy for AML

AJMC Staff
Orphan drug status applies to therapies that will treat fewer than 200,000 patients in the United States.
Study Finds Common, Lethal Cancers Need More Funding
July 26th 2019

Study Finds Common, Lethal Cancers Need More Funding

Laura Joszt, MA
Some cancers, such as breast cancer and leukemia, were well-funded compared with their incidence, mortality, and person-years of life lost, while others, such as gastrointestinal and brain cancers, were all poorly funded.
Researchers Identify 5 Risk Factors for Blood Clots in Patients With MM Treated With IMiDs
July 19th 2019

Researchers Identify 5 Risk Factors for Blood Clots in Patients With MM Treated With IMiDs

Laura Joszt, MA
Venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) who are being treated with immunomodulatory drugs (IMiDs), and a new assessment model may help to predict VTE in this population.
VA Study: Black Patients With MM See Better Survival Than White Patients With Equal Access to Therapy
July 17th 2019

VA Study: Black Patients With MM See Better Survival Than White Patients With Equal Access to Therapy

Mary Caffrey
African Americans are twice as likely to get multiple myeloma (MM) as whites, but they get the disease at younger ages.
Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia
July 13th 2019

Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia

Alison Rodriguez
With the FDA approval of a supplemental New Drug Application (sNDA) expanding the use of avatrombopag (Doptelet) for patients with chronic immune thrombocytopenia (ITP), Dova Pharmaceuticals said recently it will begin marketing the drug for the new indication in the middle of July.
Identifying Multiple Myeloma Treatment Patterns by Age and Region
July 12th 2019

Identifying Multiple Myeloma Treatment Patterns by Age and Region

Laura Joszt, MA
A poster abstract evaluated real-world treatment patterns by region and age to better understand these issues in order to address them.
Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma
July 6th 2019

Lenalidomide Proves Effective in Treating Smoldering Multiple Myeloma

Sara Karlovitch
A new study by Mayo Clinic Researchers calls into question the current standard of care for treating smoldering multiple myeloma.
SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination
July 4th 2019

SIRT1 Plays Key Role in Preventing Leukemia Stem Cell Elimination

Sara Karlovitch
Researchers from the the University of Alabama finds the SIRT1 protein plays a key role in preventing chronic myeloid leukemia stem cell elimination.
Final Thoughts on Approach to Multiple Myeloma Treatment
June 28th 2019

Final Thoughts on Approach to Multiple Myeloma Treatment

Biochemical Versus Symptomatic Relapse Treatment Choices in MM
June 28th 2019

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma
June 28th 2019

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Patient Cost Implications in Multiple Myeloma Treatment
June 28th 2019

Patient Cost Implications in Multiple Myeloma Treatment

Treatment Options in Relapsed/Refractory Multiple Myeloma
June 28th 2019

Treatment Options in Relapsed/Refractory Multiple Myeloma

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma
June 28th 2019

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma
June 28th 2019

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

The Impact of OCM in the Treatment of Multiple Myeloma
June 28th 2019

The Impact of OCM in the Treatment of Multiple Myeloma

Entering a 4-Drug Regimen for Multiple Myeloma Treatment
June 28th 2019

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

<1
...
789101112131415
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo